EGFR TKIs provide significantly longer progression-free survival compared to chemotherapy as first-line therapy for advanced EGFR-mutated NSCLC. The benefit is greatest for patients with exon 19 deletions versus exon 21 L858R mutations, never-smokers versus current/former smokers, and women versus men. Performance status, age, ethnicity, and tumor histology did not predict additional benefit from EGFR TKIs over chemotherapy.

1. EGFR TKIs VS
CHEMOTHERAPY

2. Impact of Specific EGFR+ and Clinical Characteristics
on Outcomes After Treatment With EGFR TKIs Vs
Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-
Analysis.
• Aim: the impact of different EGFR mutations
and clinical characteristics on PFS in pts with
advanced EGFR-mutated NSCLC treated with
EGFR TKIs as 1st-line therapy.
• In seven eligible trials (N=1,649 patients)
Lee CK et al. J Clin Oncol. 2015 Apr 20. pii: JCO.2014.58.1736. [Epub ahead of print]

3. RESULT
• EGFR+ = For tumors with exon 19 deletions, the
benefit was 50% greater (HR, 0.24) than for
tumors with exon 21 L858R substitution (HR,
0.48; Pinteraction < .001).
• Never-smokers had a 36% greater benefit (HR,
0.32) than current or former smokers (HR, 0.50;
Pinteraction < .001).
• Women had a 27% greater benefit (HR, 0.33)
than men (HR, 0.45; treatment-sex interaction P =
.02).
Performance status, age, ethnicity, and tumor histology did not
significantly predict additional benefit from EGFR TKIs.

4. CONCLUSION
• EGFR TKIs significantly prolonged PFS overall
and in all subgroups, compared with
chemotherapy
• Greater benefits were observed in those with
exon 19 deletions, never-smokers, and
women.

5. Key points
• PFS benefit was increased for patients with
exon 19 deletion vs those with exon 21 L858R
substitution, never-smokers vs ever smokers,
and women vs men.
• Additional benefit was not predicted by
performance status, age, ethnicity, or
histology.